Precigen (PGEN) Stock Price, News & Analysis

Company Overview

Precigen, Inc. (NASDAQ: PGEN) is a biotechnology company focused on the discovery, development and commercialization of genetic medicines. The company leverages proprietary gene and cell therapy platforms to design targeted therapies for oncology, infectious diseases and rare conditions. Precigen’s approach combines synthetic biology, immuno-oncology and microbiome engineering to create precision treatments intended to enhance efficacy while minimizing off-target effects.

The centerpiece of Precigen’s technology is its OmniCAR platform, which enables the rapid generation of adaptable chimeric antigen receptor (CAR) T-cell products. By using a modular receptor system, OmniCAR T cells can be retargeted against multiple tumor antigens through the administration of different adaptor molecules. In addition, Precigen’s ActoBiotics platform engineers live bacterial strains to deliver therapeutic payloads at disease sites, offering a novel route to treat gastrointestinal and other localized disorders.

Precigen’s clinical pipeline includes several early- to mid-stage programs. In oncology, the company is evaluating OmniCAR candidates targeting hematologic malignancies and solid tumors. The ActoBiotics pipeline features programs for inflammatory bowel disease and metabolic disorders. Precigen also maintains research collaborations and licensing partnerships aimed at expanding the utility of its gene control and vector technologies across diverse therapeutic areas.

Originally founded in 1998 as Intrexon Corporation, the company rebranded as Precigen in 2020 to reflect its strategic focus on precision genetic medicine. Headquartered in Germantown, Maryland, Precigen operates research and manufacturing sites in the United States and Europe. Under the leadership of President and CEO Helen Sabzevari, PhD, the company continues to build its pipeline and advance next-generation therapies toward regulatory milestones and commercialization.

Key Stats

• Today's Range: $3.43 to $3.63
• 50-Day Range: $1.74 to $4.76
• 52-Week Range: $0.65 to $5.22
• Volume: 4.85 million shs
• Average Volume: 4.19 million shs
• Market Capitalization: $1.04 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $8.25
• Consensus Rating: Moderate Buy

Precigen Stock Analysis - MarketRank™

Precigen scored higher than 89% of companies evaluated by MarketBeat, and ranked 94th out of 950 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.3 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Precigen has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 4 buy ratings, 1 hold rating, and 1 sell rating.

Upside Potential

Precigen has a consensus price target of $8.25, representing about 136.1% upside from its current price of $3.50.

Amount of Analyst Coverage

Precigen has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Precigen are expected to grow in the coming year, from ($0.32) to ($0.20) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Precigen is -8.35, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Precigen is -8.35, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Precigen has a P/B Ratio of 26.88. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

23.95% of the float of Precigen has been sold short.

Short Interest Ratio / Days to Cover

Precigen has a short interest ratio ("days to cover") of 4.2.

Change versus previous month

Short interest in Precigen has recently decreased by 2.16%, indicating that investor sentiment is improving.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Precigen does not currently pay a dividend.

Dividend Growth

Precigen does not have a long track record of dividend growth.

Sustainability and ESG

• Score: 4.7 / 5
• Environmental Score: -0.77

Percentage of Shares Shorted

23.95% of the float of Precigen has been sold short.

Short Interest Ratio / Days to Cover

Precigen has a short interest ratio ("days to cover") of 4.2.

Change versus previous month

Short interest in Precigen has recently decreased by 2.16%, indicating that investor sentiment is improving.

News and Social Media

• Score: 2.5 / 5
• News Sentiment: 0.48

News Sentiment

Precigen has a news sentiment score of 0.48. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.72 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 5 news articles for Precigen this week, compared to 4 articles on an average week.

Search Interest

Only 39 people have searched for PGEN on MarketBeat in the last 30 days. This is a decrease of -7% compared to the previous 30 days.

MarketBeat Follows

11 people have added Precigen to their MarketBeat watchlist in the last 30 days. This is an increase of 57% compared to the previous 30 days.

Company Ownership

• Score: 3.3 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Precigen insiders have sold 11,756.69% more of their company's stock than they have bought. Specifically, they have bought $214,467.00 in company stock and sold $25,428,688.00 in company stock.

Percentage Held by Insiders

47.10% of the stock of Precigen is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

Only 33.51% of the stock of Precigen is held by institutions.

PGEN Stock Analysis - Frequently Asked Questions

How have PGEN shares performed this year?

Precigen's stock was trading at $1.12 on January 1st, 2025. Since then, PGEN stock has increased by 212.1% and is now trading at $3.4950.

How were Precigen's earnings last quarter?

Precigen, Inc. (NASDAQ:PGEN) announced its earnings results on Tuesday, August, 12th. The biotechnology company reported ($0.11) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.14) by $0.03. The biotechnology company had revenue of $0.86 million for the quarter, compared to analyst estimates of $0.67 million. Precigen had a negative trailing twelve-month return on equity of 842.83% and a negative net margin of 2,868.66%.

Who are Precigen's major shareholders?

Top institutional investors of Precigen include Inspire Investing LLC (0.05%), Voya Investment Management LLC (0.01%), Flower City Capital (0.01%) and Vontobel Holding Ltd.. Insiders that own company stock include Randal J Kirk, Helen Sabzevari, Steven Frank, Jeffrey Thomas Perez, Harry Jr Thomasian, Donald P Lehr, Rutul R Shah, Dean J Mitchell and Jeffrey B Kindler.
View institutional ownership trends.

How do I buy shares of Precigen?

Shares of PGEN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Precigen own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Precigen investors own include Nordic American Tankers (NAT), ZIOPHARM Oncology (ZIOP), NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Hess (HES) and Boeing (BA).

Company Calendar

• Last Earnings: 8/12/2025
• Today: 10/16/2025
• Next Earnings (Estimated): 11/13/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:PGEN
• CIK: 1356090
• Web: www.precigen.com
• Phone: (301) 556-9900
• Fax: N/A
• Employees: 190
• Year Founded: 1998

Price Target and Rating

• Average Price Target for Precigen: $8.25
• High Price Target: $8.50
• Low Price Target: $8.00
• Potential Upside/Downside: +132.1%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.50
• Research Coverage: 6 Analysts

Profitability

• EPS (Trailing Twelve Months): ($0.42)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$126.24 million
• Net Margins: -2,868.66%
• Pretax Margin: -2,870.32%
• Return on Equity: -842.83%
• Return on Assets: -78.98%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 2.71
• Quick Ratio: 2.71

Sales & Book Value

• Annual Sales: $3.92 million
• Price / Sales: 270.23
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.13 per share
• Price / Book: 27.35

Miscellaneous

• Outstanding Shares: 297,970,000
• Free Float: 157,628,000
• Market Cap: $1.06 billion
• Optionable: Optionable
• Beta: 1.61